A Phase 1/2 interventional study of 68Ga-PSMA-CYC and CYC in Prostate CA, sponsored by First Affiliated Hospital of Fujian Medical University. Recruiting at 1 site in China. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-09.
Sponsored by First Affiliated Hospital of Fujian Medical University · Phase 1/2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing cyclophosphamide in Prostatic Neoplasms — 4 open to participants now, 7 under way, none of them phase 3. Cyclophosphamide · Prostatic Neoplasms.
Among the 16 studies testing cyclophosphamide in Prostatic Neoplasms, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 4 in phase 1/2, and was the 15th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →4 of the 16 studies testing cyclophosphamide in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Beijing Biotech · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–80 · Men only
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 7
First in 1999; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 19 across the 15 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 16 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital of Fujian Medical University is the lead sponsor of 97 studies on the registry; 55 are open to participants now.
15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University: 10 open now, 13 under way, 1 of them phase 3. Of 2 finished, 0 (0%) have results posted.
Among the 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 6 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 10 of the 12 other live ones, and was the 8th registered.
First Affiliated Hospital of Fujian Medical University’s Prostatic Neoplasms studies by the year they started, since 2020.
3 of the studies testing cyclophosphamide in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07056790First Affiliated Hospital of Fujian Medical UniversityResearch on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer | 2027-02 |
| NCT07523529Beijing BiotechBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | 2027-04-14 |
| NCT01140373Memorial Sloan Kettering Cancer CenterAdoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing cyclophosphamide in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among First Affiliated Hospital of Fujian Medical University’s 15 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
68Ga-PSMA-CYC is a novel radiotracer targeting PSMA. In this study, we investigated the safety, biodistribution, radiation dosimetry of 68Ga-PSMA-CYC PET/CT in patients with prostate cancer, and performed a head-to-head comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 to evaluate its diagnostic performance.
Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is highly expressed in PCa and its metastatic lesions, making it an ideal target for the precise diagnosis and treatment of PCa. Various low-molecular-weight radiopharmaceuticals targeting PSMA have been developed, such as PSMA-11 and PSMA-617, which can be labeled with 68Ga or 177Lu. 68Ga-PSMA-CYC is a novel radiotracer that has demonstrated favorable in vivo and in vitro stability in preliminary studies, with specific accumulation in PCa, high binding affinity, and good safety profile, making it a promising candidate for further investigation. This prospective study aims to investigate the safety, biodistribution, radiation dosimetry of 68Ga-PSMA-CYC PET/CT in patients with prostate cancer, and performed a head-to-head comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 to evaluate its diagnostic performance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prostate Patients received 68Ga-PSMA-CYC 、68Ga-PSMA-617 or 68Ga-PSMA-11 PET/CT imaging within one week. Tracer doses of 68Ga-PSMA-CYC、68Ga-PSMA-617 or 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT
Drug: 68Ga-PSMA-CYC
Experimental: dynamic PET scans PET imaging will begin at 3 minutes, 15 minutes, 30min minutes, 60 minutes and 150 minutes after injection
Drug: CYC
Each prostate cancer patient underwent a 68Ga-PSMA-CYC (3-4 mCi) PET/CT scan, as well as a 68Ga-PSMA-617 (3-4 mCi) or 68Ga-PSMA-11 (3-4 mCi) PET/CT scan, with the time interval between the two scans not exceeding one week.
The dose will be 3-4mCi given intravenously.
Diagnostic value
Sensitivity and Specificity of 68Ga-PSMA-CYC for prostate cancer in comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 PET/CT.
Time frame: through study completion, an average of 1year
Adverse events
The safety will be assessed by the number and percentage of patients with adverse events; Adverse events were categorized using the Common Toxicity Criteria for Adverse Events 5.0.
Time frame: Within 7 days following PET/CT
Dosimetry data
Calculate the absorbed dose of 68Ga-PSMAcyc in normal organs.
Time frame: through study completion, an average of 3 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Feb 2027, 21 months after the start.
Of 114 non-industry phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 85. This study's planned 21 months is below that.
Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclophosphamide
First Affiliated Hospital of Fujian Medical University